[新生儿喹诺酮治疗后发生的颅内高压]
[Intracranial hypertension in a newborn treated with quinolone].
作者信息
Bedu A, Naar I, Farnoux C, Brisse H, Le Huidoux P, Aujard Y
机构信息
Service de Néonatologie, Hôpital Robert Debré, Paris.
出版信息
Presse Med. 1998 Jun 27;27(23):1140-2.
BACKGROUND
Fluoroquinolones have not received administrative authorization for use in children, but because of multiresistant pathogens in neonatal intensive care, floroquinolones may be the only alternative.
CASE REPORT
A premature infant exclusively nourished by parenteral nutrition developed enterobacteria sepsis. Ceftazidine was given initially but resistance led to the prescription of fluoroquinolone. Signs of intracranial hypertension developed 3 days after onset of fluoroquinolone treatment and regressed 48 hours after its withdrawal.
DISCUSSION
The main potential adverse effects with fluoroquinone in the newborn are arthropathy, photosensitivity, discoloration of the teeth and neurological disorders. Intracranial hypertension is a known complication of nalidixic acid both in adults and children, but to our knowledge has not been previously with floroquinolone in the newborn.
背景
氟喹诺酮类药物尚未获得用于儿童的行政许可，但由于新生儿重症监护室中存在多重耐药病原体，氟喹诺酮类药物可能是唯一的选择。
病例报告
一名完全通过肠外营养喂养的早产儿发生了肠杆菌败血症。最初给予了头孢他啶，但由于耐药而改用氟喹诺酮类药物。氟喹诺酮类药物治疗开始后3天出现颅内高压症状，停药后48小时症状消退。
讨论
氟喹诺酮类药物在新生儿中的主要潜在不良反应是关节病、光敏性、牙齿变色和神经紊乱。颅内高压是成人和儿童中萘啶酸已知的并发症，但据我们所知，此前新生儿使用氟喹诺酮类药物尚未出现这种情况。
Zotero 插件